1. Açık Erişim@BUU
  2. İndeksli Yayınlar
  3. Web of Science
Bu öğeden alıntı yapmak, öğeye bağlanmak için bu tanımlayıcıyı kullanınız: http://hdl.handle.net/11452/25974
Tüm üstveri kaydı
Dublin Core AlanıDeğerDil
dc.date.accessioned2022-04-21T13:31:54Z-
dc.date.available2022-04-21T13:31:54Z-
dc.date.issued2006-08-
dc.identifier.citationErsoy, A. (2006). ''Current and future antihypertensive drugs in post-transplant hypertension and related patents''. Expert Opinion on Therapeutic Patents, 16(8), 1093-1106.en_US
dc.identifier.issn1354-3776-
dc.identifier.issn1744-7674-
dc.identifier.urihttps://doi.org/10.1517/13543776.16.8.1093-
dc.identifier.urihttps://www.tandfonline.com/doi/full/10.1517/13543776.16.8.1093-
dc.identifier.urihttp://hdl.handle.net/11452/25974-
dc.description.abstractHypertension is common in renal transplant recipients (RTR) and may contribute to the high incidence of morbidity and mortality from cardiovascular disease. Its treatment is an important factor necessary to ensure long-term patient and allograft survival. Although all anti hypertensive drugs are useful in RTRs, the most commonly used drugs are calcium-channel blockers and renin-angiotensin system inhibitors. This article briefly reviews traditional drugs together with new anti hypertensive drugs under development, focusing on their possible advantages in RTRs. In addition, many patents reporting chemical processes and pharmaceutical formulations of these drugs are also summarised.en_US
dc.language.isoenen_US
dc.publisherTaylor & Francisen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectPharmacology & pharmacyen_US
dc.subjectKidney transplantationen_US
dc.subjectHypertensionen_US
dc.subjectAntihypertensive drugsen_US
dc.subjectAce-inhibitoren_US
dc.subjectRisk-assessmenten_US
dc.subjectBlood-pressureen_US
dc.subjectOxidative stressen_US
dc.subjectKidney-transplantationen_US
dc.subjectAngiotensin-IIen_US
dc.subjectGlycation end-productsen_US
dc.subjectConverting enzyme-inhibitionen_US
dc.subjectCalcium-channel blockersen_US
dc.subjectRenal-transplant recipientsen_US
dc.titleCurrent and future antihypertensive drugs in post-transplant hypertension and related patentsen_US
dc.typeArticleen_US
dc.identifier.wos000242600200004tr_TR
dc.identifier.scopus2-s2.0-33747071450tr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Nefroloji Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0002-0710-0923tr_TR
dc.identifier.startpage1093tr_TR
dc.identifier.endpage1106tr_TR
dc.identifier.volume16tr_TR
dc.identifier.issue8tr_TR
dc.relation.journalExpert Opinion on Therapeutic Patentsen_US
dc.contributor.buuauthorErsoy, Alpaslan-
dc.contributor.researcheridAAH-5054-2021tr_TR
dc.subject.wosChemistry, medicinalen_US
dc.subject.wosPharmacology & pharmacyen_US
dc.indexed.wosSCIEen_US
dc.indexed.scopusScopusen_US
dc.wos.quartileQ3en_US
dc.contributor.scopusid35612977100tr_TR
dc.subject.scopusKidney Transplantation; Transplant Recipients; Ambulatory Blood Pressure Monitoringen_US
dc.subject.emtreeVerapamilen_US
dc.subject.emtreeValsartanen_US
dc.subject.emtreeUnindexed drugen_US
dc.subject.emtreeTelmisartanen_US
dc.subject.emtreeSteroiden_US
dc.subject.emtreeQuinaprilen_US
dc.subject.emtreePlaceboen_US
dc.subject.emtreeOlmesartanen_US
dc.subject.emtreeNitrendipineen_US
dc.subject.emtreeNifedipineen_US
dc.subject.emtreeManidipineen_US
dc.subject.emtreeLosartanen_US
dc.subject.emtreeLisinoprilen_US
dc.subject.emtreeIsradipineen_US
dc.subject.emtreeIrbesartanen_US
dc.subject.emtreeEprosartanen_US
dc.subject.emtreeEnalapril maleateen_US
dc.subject.emtreeDipeptidyl carboxypeptidase inhibitoren_US
dc.subject.emtreeDiltiazemen_US
dc.subject.emtreeCandesartan hexetil; cyclosporin Aen_US
dc.subject.emtreeCandesartanen_US
dc.subject.emtreeCalcium channel blocking agenten_US
dc.subject.emtreeCalcineurin inhibitoren_US
dc.subject.emtreeBeta adrenergic receptor blocking agenten_US
dc.subject.emtreeAtenololen_US
dc.subject.emtreeAntihypertensive agenten_US
dc.subject.emtreeAngiotensin receptor antagonisten_US
dc.subject.emtreeAngiotensin 1 receptor antagonisten_US
dc.subject.emtreeAmlodipineen_US
dc.subject.emtreeSurvival timeen_US
dc.subject.emtreeReviewen_US
dc.subject.emtreeRenin angiotensin aldosterone systemen_US
dc.subject.emtreeRashen_US
dc.subject.emtreePostoperative perioden_US
dc.subject.emtreePatenten_US
dc.subject.emtreeNephrotoxicityen_US
dc.subject.emtreeKidney transplantationen_US
dc.subject.emtreeKidney graften_US
dc.subject.emtreeHypertensionen_US
dc.subject.emtreeHyperkalemiaen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeGraft survivalen_US
dc.subject.emtreeGraft recipienten_US
dc.subject.emtreeDrug half lifeen_US
dc.subject.emtreeDrug formulationen_US
dc.subject.emtreeDrug designen_US
dc.subject.emtreeDisease exacerbationen_US
dc.subject.emtreeDiabetes mellitusen_US
dc.subject.emtreeCoughingen_US
dc.subject.emtreeClinical trialen_US
dc.subject.emtreeAngioneurotic edemaen_US
dc.subject.emtreeAnemiaen_US
dc.subject.emtreeAnaphylaxisen_US
Koleksiyonlarda Görünür:Scopus
Web of Science

Bu öğenin dosyaları:
Bu öğeyle ilişkili dosya bulunmamaktadır.
Kısa Öğe Kaydını Göster İstatistikler


DSpace'deki bütün öğeler, aksi belirtilmedikçe, tüm hakları saklı tutulmak şartıyla telif hakkı ile korunmaktadır.